Skip to Content
Merck

C4024

Carbamazepine

≥98% (HPLC), powder, sodium channel inhibitor

Synonym(s):

5H-Dibenz[b,f]azepine-5-carboxamide

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C15H12N2O
CAS Number:
298-46-4
Molecular Weight:
236.27
UNSPSC Code:
12352200
eCl@ss:
34051404
PubChem Substance ID:
57654002
NACRES:
NA.77
EC Number:
206-062-7
MDL number:
MFCD00005073
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Carbamazepine, powder

SMILES string

NC(=O)N1c2ccccc2C=Cc3ccccc13

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

form

powder

mp

191-192 °C (lit.)

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 29 mg/mL
H2O: insoluble
ethanol: soluble
propylene glycol: soluble

originator

Novartis

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... BZRAP1(9256), GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA4(2557), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRB2(2561), GABRB3(2562), PRNP(5621), SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)
rat ... Scn2a1(24766), Scnn1a(25122), Scnn1g(24768), Slc6a1(79212)

Looking for similar products? Visit Product Comparison Guide

Application

Carbamazepine has been used to investigate its behavior in wastewater treatment and during groundwater infiltration. It has also been used to find out its effects on spontaneous seizures in rats.

Biochem/physiol Actions

Anticonvulsant; ligand for the GABAA receptor benzodiazepine modulatory site. Sodium channel inhibitor.
Carbamazepine is considered as a safe antiepileptic drug. It decreases the multiple drug therapy and maintains a better control of epilepsy.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3

target_organs

Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

C4024-5G: + C4024-25G: + C4024-BULK: + C4024-1G: + C4024-10G: + C4024-VAR:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCP6334
MKCK3782
MKCF7846
MKCD9730
MKCD4902

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effect of antiepileptic drugs on spontaneous seizures in epileptic rats
Nissinen J and Pitkanen A
Epilepsy Research, 73(2), 181-191 (2007)
Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behaviour of carbamazepine in wastewater treatment and during groundwater infiltration
Clara M, et al.
Water Research, 38(4), 947-954 (2004)
Role of carbamazepine in reducing polypharmacy in epilepsy
Maheshwari MC and Padmini R
Acta Neurologica Scandinavica, 64(1), 22-28 (1981)
J P Johnson et al.
eLife, 11 (2022-03-03)
NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target NaV1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A-related epilepsy syndromes (SCN8A-RES), where gain-of-function (GoF) mutations lead to excess NaV1.6 sodium current, or other
G D C Mendis et al.
Scientific reports, 9(1), 121-121 (2019-01-16)
Determining the mechanism of action (MOA) of novel or naturally occurring compounds mostly relies on assays tailored for individual target proteins. Here we explore an alternative approach based on pattern matching response profiles obtained using cultured neuronal networks. Conolidine and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service